The clinical impact of neutralizing antibodies (NAbs) on interferon beta (IFNβ) efficacy was studied in three large patient cohorts comprising 6698 multiple sclerosis (MS) patients receiving IFNβ-1b across North America, Europe, and Australia. In North America and Europe, NAb testing was generally undertaken because of a poor clinical response; in Australia, it was mandatory for every patient. Of the 6697 patients tested, 28.9% had at least one NAb titre ≥ 20 neutralizing units (NU)/ml, 14.4% had NAb titres ≥ 100 NU/ml and 7.7% had NAb titres ≥ 400 NU/ml. The NAb-positive rate of 37.0% in Australia was significantly greater than those in North America (21.3%) and Europe (27.6%), and this was observed at every NAb titre level. Our results suggest that NAbs are not responsible for poor clinical responses and that NAb status is of little clinical value. These findings will need to be confirmed in a large independent study.
BertolottoAMalucchiSMilanoECastelloACapobiancoMMutaniR: Interferon beta neutralizing antibodies in multiple sclerosis: Neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology2000; 48: 95–100.
2.
HemmerBStuveOKieseierBSchellekensHHartungHP: Immune response to immunotherapy: The role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol2005; 4: 403–412.
3.
IFNβ Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology1993; 43: 655–661.
4.
IFNβ Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology1996; 47: 889–894.
5.
JacobsLDCookfairDLRudickRAHerndonRMRichertJR, Salazar AM, et al and the Multiple Sclerosis Collaborative Research Group (MSCRG): Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol1996; 39: 285–294.
6.
JacobsLDBeckRWSimonJHKinkelRPBrownscheidleCM, Murray TJ, et al for the CHAMPS Study Group: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med2000; 343: 898–904.
7.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet1998; 352: 1498–1504.
8.
GoodinDSFrohmanEMGarmanyGPJrHalperJLikoskyWHLublinFD: Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology2002; 58: 169–178.
9.
Francis GS, Rice GP, Alsop JC and the PRISMS Study Group: Interferon beta-1a in MS: Results following development of neutralizing antibodies in PRISMS. Neurology2005; 65: 48–55.
10.
KapposLClanetMSandberg-WollheimMRadueEWHartungHP, Hohlfeld R, et al and the European Interferon Beta-1a IM Dose-Comparison Study Investigators: Neutralizing antibodies and efficacy of interferon beta-1a: A 4-year controlled study. Neurology2005; 65: 40–47.
11.
PetkauAJWhiteRAEbersGCRederATSibleyWA, Lublin FD et al and the IFNB Multiple Sclerosis Study Group: Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler2004; 10: 126–138.
12.
PolmanCKapposLWhiteRDahlkeFBeckmannK, Pozzilli C, et al for the European Study Group in Interferon Beta-1b in Secondary Progressive MS: Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology2003; 60: 37–43.
13.
RioJTintoreMTellezNNosCGalanIMontalbanX: [Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis.]Med Clin (Barc)2005; 124: 140–141 (in Spanish).
14.
PanitchHGoodinDSFrancisGChangPCoylePKO'ConnorP: Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology2002; 59: 1496–1506.
15.
DurelliLVerdunEBarberoPBergliMVersinoEGrezziA: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet2002; 359: 1453–1460.
16.
PanitchHGoodinDSFrancisGChangPCoyleP, O'Connor P et al, the EVIDENCE Study Group, and the UBC MS/MRI Research Group: Benefits of high-dose, high-frequency interferon beta-1a in relapsing MS are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci2005; 238: 67–74.
17.
RiceGPPasznerBOgerJLesauxJPatyDEbersG: The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology1999; 52: 1277–1279.
18.
SorensenPSRossCClemmesenKMBendtzenKFrederiksenJLJensenK: The Danish Multiple Sclerosis Study Group: Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet2003; 362: 1184–1191.
19.
The North American Study Group on Interferon beta-1a in Secondary Progressive MS: Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology2004; 63: 1788–1795.
20.
HerndonRMRudickRAMunschauerFEIIIMassMKSalazarAMCoatsME: Eight-year immunogenicity and safety of interferon beta-1a-Avonex® treatment in patients with multiple sclerosis. Mult Scler2005; 11: 409–419.
21.
SorensenPSKoch-HenriksenNRossCClemmesenKMBendtzenK: Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology2005; 65: 33–39.
22.
Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology1993; 43: 655–661.
23.
The IFNB Multiple Sclerosis Study Group, the UBC MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology1995; 45: 1277–1285.
24.
European Study Group on Interferon β-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet1998; 352: 1491–1497.
25.
PRISMS Study Group, the UBC MS/MRI Analysis Group: PRISMS-4: Long-term efficacy of inter-feron-beta-1a in relapsing MS. Neurology2001; 56: 1628–1636.
26.
SPECTRIMS Study Group: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology2001; 56: 1496–1504.
27.
RudickRASimonianNAAlamJACampionMScaramucciJOJonesW: Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology1998; 50: 1266–1272.
28.
FrankJARichertNBashCStoneLCalabresiPALewisB: Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb-and NAb+ patients. Neurology2004; 62: 719–725.
29.
The IFNB Multiple Sclerosis Study Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b. Neurology1996; 47: 889–894.
30.
ClanetMRadueEWKapposLHartungHPHohlfeldR, Sandberg-Wollheim M, et al, the European IFN beta-1a (Avonex) Dose-Comparison Study Investigators: A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology2002; 59: 1507–1517.
31.
BarberoPBerguiMVersinoERicciAZhongJJ, Ferrero, B, et al, the INCOMIN Trial Study Group: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: Analysis of MRI responses to treatment and correlation with NAb. Mult Scler2006; 12: 72–76.
32.
MalucchiSSalaAGilliFBotteroRDi SapioACapobiancoM: Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology2004; 62: 2031–2037.
33.
PeriniPCalabreseM: The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol2004; 251: 305–309.
34.
GilliFSalaFHoffmannFMarnettoFCaldanoMKapposL: Anti-interferon beta neutralizing activity is not entirely mediated by antibodies. Mult Scler2005; 11 (suppl 1): S2–S3.
35.
FilesJGGrayJLDoLTFoleyWPGabeJDNestaasE: A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res1998; 18: 1019–1024.
36.
McKayFSchibeciSHeardRStewartGBoothD: Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: A comparison of three methods in a large Australasian cohort. J Immunol Methods2005; 310: 20–29.
37.
GrossbergSEKawadeYKohaseMKleinJP: The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: The tenfold reduction unit. J Interferon Cytokine Res2001; 21: 743–755.
38.
NoronhaABAntelJPRoosRPMedofME: Circulating immune complexes in neurologic disease. Neurology1981; 31: 1402–1407.
39.
NoronhaAToscasAJensenMA: Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol1990; 27: 207–210.
40.
NoronhaAToscasAArnasonBGJensenMA: IFN-beta augments in vivo suppressor function in MS. Neurology1994; 44 (suppl 2): A212.
41.
MillerALiderORobertsABSpornMBWeinerHL: Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA1992; 89: 421–425.
42.
BrennerTArnonRSelaMAbramskyOMeinerZRiven-KreitmanR: Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®. J Neuroimmunol2001; 115: 152–160.
43.
HaasJMaas-EnriquezMHartungHP: Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis –- results of a retrospective multicenter observational study over five years. Mult Scler2005; 11: 562–567.
